Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh, or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in the lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won’t heal, slower growth of toenails and erectile dysfunction in men.

The PVD pipeline drugs market research report provides comprehensive information on the therapeutics under development for PVD, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for PAD and features dormant and discontinued projects.

PVD Pipeline Drugs Market Segmentation by Targets

Some of the targets of the PVD pipeline drugs market are Hepatocyte Growth Factor, Fibroblast Growth Factor Receptor 1, Prostaglandin E2 Receptor EP1 Subtype, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Advanced Glycosylation End Product Specific Receptor, Aldehyde Dehydrogenase Mitochondrial, Bromodomain Containing Protein 4, Cannabinoid Receptor 1, Cannabinoid Receptor 2, and Decorin.

PVD Pipeline Drugs Market Analysis, by Targets

For more PAD pipeline drugs market target insights, download a free report sample

PAD Pipeline Drugs Market Segmentation by Mechanism of Actions

Some of the mechanisms of action of the PVD pipeline drugs market are Hepatocyte Growth Factor Activator, Fibroblast Growth Factor Receptor 1 Agonist, Prostaglandin E2 Receptor EP1 Subtype Agonist, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Advanced Glycosylation End Product Specific Receptor Antagonist, Aldehyde Dehydrogenase Mitochondrial Activator, Bromodomain Containing Protein 4 Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, and Dipeptidyl Peptidase 4 Inhibitor.

PAD Pipeline Drugs Market Analysis, by Mechanism of Actions

For more mechanism of action insights into the PVD pipeline drugs market, download a free report sample

PVD Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the PVD pipeline drugs market are intramuscular, intravenous, oral, subcutaneous, parenteral, intracardiac, topical, epidural, intraarterial, and intraarticular.

PAD Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the PAD pipeline drugs market, download a free report sample

PVD Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the PVD pipeline drugs market are Small Molecule, Cell Therapy, Gene Therapy, Protein, Recombinant Protein, Synthetic Peptide, Monoclonal Antibody, Biologic, Gene-Modified Cell Therapy, Oligonucleotide, Peptide, and Recombinant Peptide.

PAD Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the PVD pipeline drugs market, download a free report sample

Competitive Landscape

Some of the key companies in the PVD pipeline drugs market are Helixmith Co Ltd, LTT Bio-Pharma Co Ltd, MediaPharma SRL, Reven Holdings Inc, Venturis Therapeutics Inc, VESSL Therapeutics Ltd, Alucent Biomedical Inc, AnGes Inc, AptaBio Therapeutics Inc, and ARCA biopharma Inc.

PVD Pipeline Drugs Market Analysis, by Companies

To know more about the PAD pipeline drugs market companies, download a free report sample

PAD Pipeline Drugs Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) or Peripheral Vascular Disease (PVD).
• The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) or Peripheral Vascular Disease (PVD) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Peripheral Arterial Disease (PAD) or Peripheral Vascular Disease (PVD) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) and Peripheral Vascular Disease (PVD).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.